A further work by the same group demonstrated that Orkambi® (Vertex Pharmaceuticals, Boston, MA, USA, CFTR VX-809 corrector + VX-770 potentiator) improved wound repair in primary cultures of CF airway epithelial cells [184], as we shall discuss in the Section 4 “Modulation of wound repair in CF”. The gene discussed is CFTR; the disease is cystic fibrosis.